US 11,730,696 B2
Cell associated scaffolds for delivery of agents
Bernard Tuch, Maroubra (AU); Tim Dargaville, The Gap (AU); Auvro Mridha, Glenfield (AU); Paul Dalton, Bavaria (DE); and Vijayaganapathy Vaithilingam, Pondicherry (IN)
Assigned to AUSTRALIAN FOUNDATION FOR DIABETES RESEARCH, Maroubra (AU)
Appl. No. 16/340,555
Filed by AUSTRALIAN FOUNDATION FOR DIABETES RESEARCH, Maroubra (AU)
PCT Filed Oct. 18, 2017, PCT No. PCT/AU2017/051126
§ 371(c)(1), (2) Date Apr. 9, 2019,
PCT Pub. No. WO2018/071967, PCT Pub. Date Apr. 26, 2018.
Claims priority of application No. 2016904265 (AU), filed on Oct. 20, 2016.
Prior Publication US 2019/0254959 A1, Aug. 22, 2019
Int. Cl. A61K 9/00 (2006.01); A61L 27/54 (2006.01); A61L 27/56 (2006.01); A61L 27/20 (2006.01); A61K 35/39 (2015.01); A61L 27/38 (2006.01); A61P 3/10 (2006.01); A61K 47/34 (2017.01); A61F 2/02 (2006.01); B33Y 80/00 (2015.01); B33Y 70/00 (2020.01); A61K 38/28 (2006.01); A61L 27/18 (2006.01); A61P 1/16 (2006.01); A61P 25/16 (2006.01); B33Y 10/00 (2015.01); A61F 2/00 (2006.01); A61K 35/12 (2015.01)
CPC A61K 9/0024 (2013.01) [A61F 2/022 (2013.01); A61K 35/39 (2013.01); A61K 38/28 (2013.01); A61K 47/34 (2013.01); A61L 27/18 (2013.01); A61L 27/20 (2013.01); A61L 27/3804 (2013.01); A61L 27/54 (2013.01); A61L 27/56 (2013.01); A61P 1/16 (2018.01); A61P 3/10 (2018.01); A61P 25/16 (2018.01); B33Y 80/00 (2014.12); A61F 2002/0086 (2013.01); A61K 2035/128 (2013.01); A61L 2300/252 (2013.01); A61L 2300/43 (2013.01); A61L 2300/62 (2013.01); A61L 2300/64 (2013.01); B33Y 10/00 (2014.12)] 14 Claims
 
1. A method for delivering an agent to a subject consisting of associating cells that produce said agent with a scaffold, and implanting said scaffold-associated cells subcutaneously in said subject, wherein the scaffold increases vascularisation at the site of subcutaneous implantation when compared to subcutaneous implantation of the same cell type without said scaffold and enhances the viability of the scaffold-associated cell after implantation by promoting vascularization at the site of implantation, and wherein the cells are encapsulated,
wherein the scaffold comprises a lid region or a base region comprising cubic pores with maximum dimensions ranging from 5 μm to 25 μm, and a centre region comprising cubic pores with maximum dimension of 2000 μm and a minimum dimension of at least 500 μm, wherein the pores of the centre region are large enough to allow a single encapsulated cell to be housed.